AUTHOR=Conti Filho Carlos Elias , Loss Lairane Bridi , Marcolongo-Pereira Clairton , Rossoni Junior Joamyr Victor , Barcelos Rafael Mazioli , Chiarelli-Neto Orlando , Silva Bruno Spalenza da , Passamani Ambrosio Roberta , Castro Fernanda Cristina de Abreu Quintela , Teixeira Sarah Fernandes , Mezzomo Nathana Jamille TITLE=Advances in Alzheimer’s disease’s pharmacological treatment JOURNAL=Frontiers in Pharmacology VOLUME=14 YEAR=2023 URL=https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1101452 DOI=10.3389/fphar.2023.1101452 ISSN=1663-9812 ABSTRACT=

Alzheimer’s disease (AD) is the most common type of dementia in the elderly. Several hypotheses emerged from AD pathophysiological mechanisms. However, no neuronal protective or regenerative drug is available nowadays. Researchers still work in drug development and are finding new molecular targets to treat AD. Therefore, this study aimed to summarize main advances in AD pharmacological therapy. Clinical trials registered in the National Library of Medicine database were selected and analyzed accordingly to molecular targets, therapeutic effects, and safety profile. The most common outcome was the lack of efficacy. Only seven trials concluded that tested drugs were safe and induced any kind of therapeutic improvement. Three works showed therapeutic effects followed by toxicity. In addition to aducanumab recent FDA approval, antibodies against amyloid-β (Aβ) showed no noteworthy results. 5-HT6 antagonists, tau inhibitors and nicotinic agonists’ data were discouraging. However, anti-Aβ vaccine, BACE inhibitor and anti-neuroinflammation drugs showed promising results.